The anti-proliferative effects of enterolactone in prostate cancer cells: Evidence for the role of DNA licencing genes, Mi-R106b cluster expression, And PTEN dosage

Nutrients

Volumn 6, Issue 11, 2014, Pages 4839-4855

  McCann, Mark J ^a,b   Rowland, Ian R ^c   Roy, Nicole C ^a,b,d  

^a AGRESEARCH GRASSLANDS   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Department of Food and Nutritional Sciences ^*  (United Kingdom)

^d MASSEY UNIVERSITY   (New Zealand)

Author keywords

Enterolactone; Lignan; miR 106b cluster; Proliferation; Prostate; PTEN

Indexed keywords

ENTEROLACTONE; ETOPOSIDE; MESSENGER RNA; MICRORNA; MICRORNA 106B; MICRORNA 25; MICRORNA 93; UNCLASSIFIED DRUG; 2,3-BIS(3'-HYDROXYBENZYL)BUTYROLACTONE; GAMMA BUTYROLACTONE; LIGNAN; MIRN106 MICRORNA, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL VIABILITY ASSAY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE EXPRESSION REGULATION; GMNN GENE; GROWTH RATE; HUMAN; HUMAN CELL; METABOLIC ACTIVITY ASSAY; MINICHROMOSOME MAINTENANCE PROTEIN 2 GENE; MINICHROMOSOME MAINTENANCE PROTEIN 7 GENE; PROSTATE CANCER CELL LINE; REAL TIME POLYMERASE CHAIN REACTION; REPLICATION LICENSING FACTOR CDT1 GENE; SPECTROPHOTOMETRY; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENETICS; MALE; METABOLISM; MITOCHONDRION; PROSTATE TUMOR; TUMOR CELL LINE;

4-BUTYROLACTONE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGNANS; MALE; MICRORNAS; MITOCHONDRIA; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER;

EID: 84908463033     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu6114839     Document Type: Article

References (50)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69–90.
2. Center, M.M.; Jemal, A.; Lortet-Tieulent, J.; Ward, E.; Ferlay, J.; Brawley, O.; Bray, F. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 2012, 61, 1079–1092.
3. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893–2917.
4. Baade, P.D.; Youlden, D.R.; Krnjacki, L.J. International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol. Nutr. Food Res. 2009, 53, 171–184.
5. Cullen, J.; Elsamanoudi, S.; Brassell, S.A.; Chen, Y.; Colombo, M.; Srivastava, A.; McLeod, D.G. The burden of prostate cancer in Asian nations. J. Carcinog. 2012, 11, 7.
6. Venkateswaran, V.; Klotz, L.H. Diet and prostate cancer: Mechanisms of action and implications for chemoprevention. Nat. Rev. Urol. 2010, 7, 442–453.
7. Khan, N.; Afaq, F.; Mukhtar, H. Lifestyle as risk factor for cancer: Evidence from human studies. Cancer Lett. 2010, 293, 133–143.
8. Muller, D.C.; Severi, G.; Baglietto, L.; Krishnan, K.; English, D.R.; Hopper, J.L.; Giles, G.G. Dietary patterns and prostate cancer risk. Cancer Epidemiol. Biomark. Prev. 2009, 18, 3126–3129.
9. Saarinen, N.M.; Tuominen, J.; Pylkkanen, L.; Santti, R. Assessment of information to substantiate a health claim on the prevention of prostate cancer by lignans. Nutrients 2010, 2, 99–115.
10. Adlercreutz, H. Lignans and human health. Crit. Rev. Clin. Lab. Sci. 2007, 44, 483–525.
11. McCann, M.J.; Gill, C.I.; McGlynn, H.; Rowland, I.R. Role of mammalian lignans in the prevention and treatment of prostate cancer. Nutr. Cancer 2005, 52, 1–14.
12. Kuhnle, G.G.; Dell’Aquila, C.; Aspinall, S.M.; Runswick, S.A.; Mulligan, A.A.; Bingham, S.A. Phytoestrogen content of foods of animal origin: Dairy products, eggs, meat, fish, and seafood. J. Agric. Food Chem. 2008, 56, 10099–10104.
13. Setchell, K.D.; Lawson, A.M.; Mitchell, F.L.; Adlercreutz, H.; Kirk, D.N.; Axelson, M. Lignans in man and in animal species. Nature 1980, 287, 740–742.
14. Woting, A.; Clavel, T.; Loh, G.; Blaut, M. Bacterial transformation of dietary lignans in gnotobiotic rats. FEMS Microbiol. Ecol. 2010, 72, 507–514.
15. Clavel, T.; Borrmann, D.; Braune, A.; Dore, J.; Blaut, M. Occurrence and activity of human intestinal bacteria involved in the conversion of dietary lignans. Anaerobe 2006, 12, 140–147.
16. Clavel, T.; Henderson, G.; Engst, W.; Dore, J.; Blaut, M. Phylogeny of human intestinal bacteria that activate the dietary lignan secoisolariciresinol diglucoside. FEMS Microbiol. Ecol. 2006, 55, 471–478.
17. Saarinen, N.M.; Thompson, L.U. Prolonged administration of secoisolariciresinol diglycoside increases lignan excretion and alters lignan tissue distribution in adult male and female rats. Br. J. Nutr. 2010, 104, 833–841.
18. McCann, M.J.; Gill, C.I.; Linton, T.; Berrar, D.; McGlynn, H.; Rowland, I.R. Enterolactone restricts the proliferation of the LNCaP human prostate cancer cell line in vitro. Mol. Nutr. Food Res. 2008, 52, 567–580.
19. McCann, M.J.; Rowland, I.R.; Roy, N.C. Anti-proliferative effects of physiological concentrations of enterolactone in models of prostate tumourigenesis. Mol. Nutr. Food Res. 2013, 57, 212–224.
20. Chen, L.H.; Fang, J.; Li, H.; Demark-Wahnefried, W.; Lin, X. Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway. Mol. Cancer Ther. 2007, 6, 2581–2590.
21. Lin, X.; Switzer, B.R.; Demark-Wahnefried, W. Effect of mammalian lignans on the growth of prostate cancer cell lines. Anticancer Res. 2001, 21, 3995–3999.
22. Morton, M.S.; Chan, P.S.; Cheng, C.; Blacklock, N.; Matos-Ferreira, A.; Abranches-Monteiro, L.; Correia, R.; Lloyd, S.; Griffiths, K. Lignans and isoflavonoids in plasma and prostatic fluid in men: Samples from Portugal, Hong Kong, and the United Kingdom. Prostate 1997, 32, 122–128.
23. Adlercreutz, H.; Bannwart, C.; Wahala, K.; Makela, T.; Brunow, G.; Hase, T.; Arosemena, P.J.; Kellis, J.T., Jr.; Vickery, L.E. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J. Steroid Biochem. Mol. Biol. 1993, 44, 147–153.
24. Masai, H.; Matsumoto, S.; You, Z.; Yoshizawa-Sugata, N.; Oda, M. Eukaryotic chromosome DNA replication: Where, when, and how? Annu. Rev. Biochem. 2010, 79, 89–130.
25. Luo, J.H. Oncogenic activity of MCM7 transforming cluster. World J. Clin. Oncol. 2011, 2, 120–124.
26. Hook, S.S.; Lin, J.J.; Dutta, A. Mechanisms to control rereplication and implications for cancer. Curr. Opin. Cell Biol. 2007, 19, 663–671.
27. Lau, E.; Tsuji, T.; Guo, L.; Lu, S.H.; Jiang, W. The role of pre-replicative complex (pre-RC) components in oncogenesis. FASEB J. 2007, 21, 3786–3794.
28. Montanari, M.; Macaluso, M.; Cittadini, A.; Giordano, A. Role of geminin: from normal control of DNA replication to cancer formation and progression? Cell Death Differ. 2006, 13, 1052–1056.
29. Ren, B.; Yu, G.; Tseng, G.C.; Cieply, K.; Gavel, T.; Nelson, J.; Michalopoulos, G.; Yu, Y.P.; Luo, J.H. MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 2006, 25, 1090–1098.
30. Honeycutt, K.A.; Chen, Z.; Koster, M.I.; Miers, M.; Nuchtern, J.; Hicks, J.; Roop, D.R.; Shohet, J.M. Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis. Oncogene 2006, 25, 4027–4032.
31. Xouri, G.; Lygerou, Z.; Nishitani, H.; Pachnis, V.; Nurse, P.; Taraviras, S. Cdt1 and geminin are down-regulated upon cell cycle exit and are over-expressed in cancer-derived cell lines. Eur. J. Biochem. 2004, 271, 3368–3378.
32. Chen, Z.; Trotman, L.C.; Shaffer, D.; Lin, H.K.; Dotan, Z.A.; Niki, M.; Koutcher, J.A.; Scher, H.I.; Ludwig, T.; Gerald, W.; et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436, 725–730.
33. Pourmand, G.; Ziaee, A.A.; Abedi, A.R.; Mehrsai, A.; Alavi, H.A.; Ahmadi, A.; Saadati, H.R. Role of PTEN gene in progression of prostate cancer. Urol. J. 2007, 4, 95–100.
34. Vlietstra, R.J.; van Alewijk, D.C.; Hermans, K.G.; van Steenbrugge, G.J.; Trapman, J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 1998, 58, 2720–2723.
35. Poliseno, L.; Salmena, L.; Riccardi, L.; Fornari, A.; Song, M.S.; Hobbs, R.M.; Sportoletti, P.; Varmeh, S.; Egia, A.; Fe dele, G. et al. Identification of the miR-106b∼25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci. Signal. 2010, 3, ra29.
36. Webber, M.M.; Quader, S.T.; Kleinman, H.K.; Bello-DeOcampo, D.; Storto, P.D.; Bice, G.; DeMendonca-Calaca, W.; Williams, D.E. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate 2001, 47, 1–13.
37. Horoszewicz, J.S.; Leong, S.S.; Chu, T.M.; Wajsman, Z.L.; Friedman, M.; Papsidero, L.; Kim, U.; Chai, L.S.; Kakati, S.; Arya, S.K. et al. The LNCaP cell line—A new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 1980, 37, 115–132.
38. Van Engeland, M.; Nieland, L.J.; Ramaekers, F.C.; Schutte, B.; Reutelingsperger, C.P. Annexin V-affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998, 31, 1–9.
39. Arentson, E.; Faloon, P.; Seo, J.; Moon, E.; Studts, J.M.; Fremont, D.H.; Choi, K. Oncogenic potential of the DNA replication licensing protein CDT1. Oncogene 2002, 21, 1150–1158.
40. Blow, J.J.; Gillespie, P.J. Replication licensing and cancer—A fatal entanglement? Nat. Rev. Cancer 2008, 8, 799–806.
41. Lei, M. The MCM complex: Its role in DNA replication and implications for cancer therapy. Curr. Cancer Drug Targets 2005, 5, 365–380.
42. Sterner, J.M.; Dew-Knight, S.; Musahl, C.; Kornbluth, S.; Horowitz, J.M. Negative regulation of DNA replication by the retinoblastoma protein is mediated by its association with MCM7. Mol. Cell. Biol. 1998, 18, 2748–2757.
43. Mukherjee, P.; Winter, S.L.; Alexandrow, M.G. Cell cycle arrest by transforming growth factor beta1 near G1/S is mediated by acute abrogation of prereplication complex activation involving an Rb-MCM interaction. Mol. Cell. Biol. 2010, 30, 845–856.
44. Shi, Y.K.; Yu, Y.P.; Zhu, Z.H.; Han, Y.C.; Ren, B.; Nelson, J.B.; Luo, J.H. MCM7 interacts with androgen receptor. Am. J. Pathol. 2008, 173, 1758–1767.
45. Evans, C.P.; Lara, P.N., Jr. Prostate cancer: Predicting response to androgen receptor signalling inhibition. Nat. Rev. Urol. 2014, 11, 433–435.
46. Balk, S.P. Androgen receptor functions in prostate cancer development and progression. Asian J. Androl. 2014, 16, 561–564.
47. Song, M.S.; Salmena, L.; Pandolfi, P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13, 283–296.
48. Sarker, D.; Reid, A.H.; Yap, T.A.; de Bono, J.S. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin. Cancer Res. 2009, 15, 4799–4805.
49. Abbas, T.; Dutta, A. p21 in cancer: Intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9, 400–414.
50. Berger, A.H.; Knudson, A.G.; Pandolfi, P.P. A continuum model for tumour suppression. Nature 2011, 476, 163–169.